-
-
Pfizer's Talzenna Label Bid Faces Setback
FDA
The FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
-
FDA Panel Supports Darzalex for Early Myeloma
Darzalex
Johnson & Johnson's Darzalex Faspro gains FDA advisory backing as a potential first treatment for high-risk smoldering multiple myeloma, despite concerns over trial design, patient selection, and long-term efficacy.
-
-
-
FDA Approvals Summary - April 2025
FDA Drug Approvals
Discover the FDA's new drug approvals in April 2025, including treatments for IgAN, nasopharyngeal carcinoma, myasthenia gravis, and colorectal cancer. Learn about groundbreaking therapies like Vanrafia, Penpulimab-KCQX, and Imaavy.
-
-
FDA Drug Rejections (January-April 2025)
FDA
From January to April 2025, the FDA rejected six new drug applications, citing issues like clinical data, CMC problems, and third-party manufacturing concerns. Learn more about each case.
-
-
The Cost of Attacking the Pharmaceutical Industry
Trump
Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
调兵山市|
南平市|
陆良县|
靖边县|
红原县|
五莲县|
达拉特旗|
平舆县|
靖安县|
壶关县|
洛浦县|
涟源市|
四子王旗|
云龙县|
安丘市|
屯门区|
淮阳县|
东城区|
利津县|
舟曲县|
怀宁县|
太白县|
界首市|
江川县|
襄垣县|
商丘市|
比如县|
克山县|
远安县|
咸阳市|
乐亭县|
岱山县|
全州县|
永登县|
涞源县|
黑河市|
吉水县|
潮安县|
广元市|
杂多县|
乌苏市|